Nektar Therapeutics Q2 revenue drops 52%

Nektar Therapeutics

07/08/2025 21:23

Overview

Nektar Therapeutics Q2 2025 revenue falls to $11.2 mln from $23.5 mln year-over-year

Net loss narrows to $41.6 mln from $52.4 mln in Q2 2024

Rezpegaldesleukin shows promising Phase 2b data; FDA grants Fast Track for alopecia areata

Outlook

Nektar expects cash to support operations into Q1 2027

Company to report 52-week rezpegaldesleukin data in early 2026

Nektar to advance NKTR-0165 into clinic in 2026

Company to report alopecia areata study data in December 2025

Result Drivers

REVENUE DECLINE - Revenue decreased due to the sale of the Huntsville manufacturing facility, ending product sales

R&D EXPENSES - Increased due to development of rezpegaldesleukin and NKTR-0165, partially offset by decreased spending on NKTR-255

COST REDUCTION - Operating costs fell due to the elimination of cost of goods sold and lower restructuring charges

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$11.18 mln
Q2 EPS
-$2.95
Q2 Net Income
-$41.59 mln
Q2 Income From Operations
-$36.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nektar Therapeutics is $95.00, about 76.4% above its August 6 closing price of $22.45

Press Release: ID:nPn8W38pPa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)